ClinicalTrials.gg
RecruitingNCT05019846SPAUpdated Apr 18, 2023

SRT Versus SRT+ADT in Prostate Cancer

A Phase 3 interventional study of Triptorelin Embonate and Bicalutamide 50 mg in Prostate Cancer, sponsored by Marco Lorenzo Bonu. Recruiting at 1 site in Italy. Open to male participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-04-18.

Sponsored by Marco Lorenzo Bonu · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 11 months ago, but the record still lists the study as recruiting.
  • Started Sep 2021; still recruiting 5 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
310
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 28 studies testing triptorelin in Prostatic Neoplasms — 6 open to participants now, 6 under way, 3 of them phase 3. triptorelin · Prostatic Neoplasms.

Planned enrollment
6th of 28
310 · median 120
Started
2021
with 1 other
Phase 3
12 of 28
2 open now
Registered
19th of 28
by date

Among the 28 studies testing triptorelin in Prostatic Neoplasms, this one is the 6th largest by planned enrollment, is one of 2 that started in 2021, is one of 12 in phase 3, and was the 19th registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

6 of the 28 studies testing triptorelin in Prostatic Neoplasms are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

About triptorelin

triptorelin: first FDA approval 2000 (TRELSTAR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years to 80 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies testing triptorelin in Prostatic Neoplasms, or all of them as a file.
02

Study summary

To clarify the role of short-term Androgen deprivation therapy (ADT) in the context of intermediate unfavorable and a subclass of high-risk patients treated with prostate Stereotactic radiotherapy (SRT).

In intermediate unfavorable risk group, when choosing standard external beam radiotherapy, short term ADT is superior in terms of biochemical disease free survival (bDFS) to EBRT alone. In high risk disease, results of the combination therapy are even more clear. Prostate SRT has been endorsed as option for primary radical treatment for prostate cancer. In such patients, the benefit of ADT is still unknown and the decision is left to clinical judgement.

For these reasons, it seems to be relevant to propose a randomized, open label, phase III clinical trial of prostate SBRT + 6 months ADT versus prostate SBRT alone in intermediate unfavorable and a subgroup of high risk prostate cancer patients.

03

Conditions studied

  • Prostate Cancer

Browse trials for

Keywords

  • SRT
  • ADT
  • SBRT
  • high risk prostate cancer
  • unfavourable intermediate risk prostate cancer
  • randomized trial
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Histological confirmation of prostate acinar adenocarcinoma with a minimum of 10 cores taken
  • Prostate protocol MRI for local staging
  • Patients belonging to intermediate unfavorable group according to the D'Amico/NCCN risk group classification:

    • -Grade group 3 or/and
    • -2-3 risk factors for intermediate category (PSA 10-20 ng/ml/ Grade group 2-3/ cT2b cT2c) or/and
    • -biopsy cores positive ≥50%
  • Patients belonging to a subclass of high risk group according to the D'Amico/NCCN risk group classification:

    • -ISUP group 4 (GS 4+4, 3+5, 5+3) or
    • -cT3a stage or
    • PSA>20
  • Eastern Coooperative Oncology Group () PS 0-2
  • Ability of the patient to understand and sign a written document
  • Ability and willingness to comply with patients reported outcome questionnaires schedule during the study time
  • IPSS 0-15
  • Prostate Volume less than 100cc
  • PSA must be dosed maximum 60 days before randomization
  • No pathologic lymph nodes and distant on PET (fluorocholine) scan or CT scan+bone scan.
  • measures for patients with partners with must be explained

Exclusion criteria

Exclusion Criteria:

  • History of Malignant tumors in the previous 2 years excluding non melanoma cancers of the skin. If a patient presents an anamnesis of (excluding non melanoma skin cancers) it must be free from disease since 24 months at the time of enrollement.
  • Previous prostate surgery other than TURP (at least 6 weeks prior to start of SBRT).
  • Previous pelvic RT
  • Prior androgen deprivation therapy (excluding 5alpha reductase inhibitors)
  • Any prior active treatment for prostate cancer; patients on previous active surveillance are eligible if inclusion criteria are met
  • Active severe inflammatory bowel disease
  • Bilateral hip prothesis or any implant that could seriously interfere with dosimetric calculations
  • Age >80 years.
  • cT4a, cT3b or pelvic lymph node involvement
  • Controindication or to the use of Triptoreline
  • 5alpha reductase inhibitors not discontinued 4 weeks prior to randomization
  • History of bone fractures and fall
  • Risk factors for abnormal heart rhythms or .
  • Use of concomitant medications that prolong the QT/QTc interval
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
310 participants (estimated)

Study arms

  • Experimental
    SRT+ADT

    Patients in ARM A will be treated with SRT on the prostate (consecutive days or at alternate days to a total dose of 36.25 Gy administered in 5 fraction (7.25 Gy/fraction) + LHRH analogue (Triptoreline 22.5 mg). An anti-androgen drug (es. Bicalutamide 50 mg) must be administered daily starting from 7 days before LHRH analogue administration to 10 days after to prevent the flare effect

    Drug: Triptorelin Embonate · Drug: Bicalutamide 50 mg

  • No intervention
    SRT alone

    Patients in ARM B will be treated with SRT on prostate alone at a total dose of 36.25 Gy administered daily or on alternate days in 5 fraction (7.25 Gy/fraction).

Interventions

06

What researchers measure

Primary outcomes

  1. biochemical disease free survival

    form the date of the end of radiotherapy to the date of PSA meeting protocol criteria for biochemical relapse or last Follow-up visit. Outcome is mesured in months.

    Time frame: outcome will be evaluated at the completion of 5 years of follow-up

Secondary outcomes

  1. Disease free survival

    from the date of the end of radiotherapy to the date of relapse (any) or last Follow-up visit.Outcome is mesured in months.

    Time frame: outcome will be evaluated at the completion of 5 years of follow-up

  2. freedom from local recurrence

    from the date of the end of radiotherapy to the date of local relapse or last Follow-up visit. Outcome is mesured in months.

    Time frame: outcome will be evaluated at the completion of 5 years of follow-up

  3. freedom from regional recurrence

    from the date of the end of radiotherapy to the date of regional relapse or last Follow-up visit. Outcome is mesured in months.

    Time frame: outcome will be evaluated at the completion of 5 years of follow-up

  4. freedom from distant metastasis

    from the date of the end of radiotherapy to the date of metastatic relapse or last Follow-up visit. Outcome is mesured in months.

    Time frame: outcome will be evaluated at the completion of 5 years of follow-up

  5. Overall survival

    from the date of the end of radiotherapy to the date of death 8any cause) or last Follow-up visit. Outcome is mesured in months.

    Time frame: outcome will be evaluated at the completion of 5 years of follow-up

  6. quality of life, prostate related quality of life in prostate cancer

    scored with questionnaire Expandend Prostate cancer Index Composite-26 (EPIC-26), score scale is 0-100 with higher scores representing better health related quality of life

    Time frame: 12 weeks after SRT, 3, 6 and 12 months after SRT

  7. quality of life, prostate related quality of life questionnarire

    scored with questionnaire European organization for research and treatment of cancer PR 25, (EORTC PR 25), All of the scales and single-item measures range in score from 0 to 100. A high score for the Sexual Activity and Sexual Functioning scales represents a high level of functioning, whereas a high score for the Urinary, Bowel, and Hormonal Treatment Related symptoms scales and Incontinence Aid item represents a high level of symptomatology or problems.

    Time frame: 12 weeks after SRT, 3, 6 and 12 months after SRT

  8. patients reported outcome, erectile function assessment,

    scored with questionnaire International Index of Erectile Function 5 (IIEF from 25 (best) to 5 (worse))

    Time frame: 12 weeks after SRT, 3, 6 and 12 months after SRT

  9. patients reported outcome, prostate related symptoms assessment

    scored with questionnaire Internation Prostate syntoms scale (IPSS, from 0 (best) to 35 (worse))

    Time frame: 12 weeks after SRT, 3, 6 and 12 months after SRT

  10. Clinician reported Acute Toxicity, assessed with CTCAE 5.0 scales

    Outcome is mesured in 0-5 scale (higher scale worse toxicity)

    Time frame: from the beginning of treatment until 6 months after SRT

  11. Clinician reported Late Toxicity, assessed with CTCAE 5.0 scales

    Outcome is mesured in 0-5 scale (higher scale worse toxicity)

    Time frame: from 6 months after SRT 5 years of follow-up

07

Study locations

1 of 1 sites recruiting
  • ASST Spedali Civili of Brescia
    Brescia, BS 25123, Italy
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Concurrently with the publication of study results concerning efficacy, we will deliver a completely deidentified data set to an appropriate data archive for sharing purposes.

Supporting information: Study protocol

Time frame: Concurrently with the publication of study results concerning efficacy, we will deliver a completely deidentified data set to an appropriate data archive for sharing purposes.

Access criteria: explicit request

Data sharing details ↗ · gmail.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2021 (actual). Primary completion is estimated for Dec 2025, 50 months after the start.

Of 139 non-industry phase 3 interventional studies under Prostatic Neoplasms, half reached primary completion within 99 months of starting (the median), counting those still running; a quarter within 57 and three quarters within 144. This study's planned 50 months is below that.

Counting every sponsor, half of 266 studies reached it within 57 months; a quarter within 31 and three quarters within 100.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 2, 2021
First posted
Aug 25, 2021
StartActual
Sep 30, 2021
Primary completionEst.
Dec 1, 2025
CompletionEst.
Dec 1, 2029
Last update
Apr 18, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 18, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05019846
Lead sponsor
Marco Lorenzo Bonu
Collaborators
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Responsible party
Marco Lorenzo Bonu (MD, Scientific coordinator, Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia) — Sponsor-investigator
First posted
Aug 25, 2021
Start date
Sep 30, 2021
Primary completion
Dec 1, 2025 (estimated)
Completion
Dec 1, 2029 (estimated)
Last update
Apr 18, 2023

Study contacts

Marco Lorenzo Bonù, MD
Contact
marco.bonu@unibs.it
+390303995285
Luca Triggiani, MD PHD
principal investigator · Università degli Studi di Brescia

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Triptorelin · Bicalutamide

Start the discussion